To Evaluate the Efficacy and Safety of Hearticelgram®-AMI in Patients With Acute Myocardial Infarction.
NCT01652209
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
90
Enrollment
INDUSTRY
Sponsor class
Conditions
Acute Myocardial Infarction
Interventions
BIOLOGICAL:
Hearticellgram-AMI
Sponsor
Pharmicell Co., Ltd.